INVESTIGATING THE ROLE OF PROBIOTICS AND SHORT-CHAIN FATTY ACIDS (SCFAs) IN MODULATING LEPTIN FOR IMPROVED ANTI-DIABETIC EFFECTS IN STREPTOZOTOCIN-NICOTINAMIDE INDUCED TYPE II DIABETES IN RATS

P. RAJYALAKSHMI DEVI; MOTE SRINATH; B. MAHESHWARI REDDY; KOPPALA R. V. S CHAITANYA; M. VINYAS

doi:10.22159/ijap.2025v17i6.54383

Authors

P. RAJYALAKSHMI DEVI Department of Pharmacology, GITAM School of Pharmacy, GITAM Deemed to be University, Hyderabad, India https://orcid.org/0009-0008-2405-7657
MOTE SRINATH Viral Research and Diagnostic Laboratory, Department of Microbiology, Osmania Medical College, Hyderabad, India https://orcid.org/0000-0003-4665-5240
B. MAHESHWARI REDDY Joginapally B. R Pharmacy College, Yenkapally, Moinabad, India https://orcid.org/0009-0005-8904-0707
KOPPALA R. V. S CHAITANYA Department of Pharmacology, Sarojini Naidu Vanita Pharmacy Maha Vidyalaya Tarnaka, Secunderabad, India https://orcid.org/0000-0002-3358-4642
M. VINYAS Department of Pharmacology, GITAM School of Pharmacy, GITAM Deemed to be University, Hyderabad, India

DOI:

https://doi.org/10.22159/ijap.2025v17i6.54383

Keywords:

Type II diabetes, Leptin, Probiotics, Butyrate, Wistar albino rats

Abstract

Objective: The gut microbiota, such as Lactobacillus rhamnosus and Bifidobacteriumlongum produces short-chain fatty acids like acetate, propionate, and butyrate from fermentation of undigested fiber, holds promise for managing metabolic diseases, including type II diabetes and obesity. This study explores the potential of probiotics and short-chain fatty acids to modulate leptin for increased anti-diabetic action in rats, offering hope for future diabetes management strategies.

Methods: Rats weighing 150 and 200 g were chosen for the study, divided into multiple groups, and given a single dose of nicotinamide and streptozotocin to induce type II diabetes. Probiotics, butyrate, propionate, and glibenclamide were continually given to respective groups after the induction of Type II diabetes. Every week, the animal's body weight was determined. Following the study's conclusion, blood was drawn via retro-orbital puncture to test the following parameters: insulin, leptin, lipid, liver, and kidney profiles. Liver and pancreas were isolated for histopathological analysis.

Results: In rats with type II diabetes, fasting blood glucose levels were significantly increased (p<0.001) compared with the normal control group, accompanied by a marked reduction in fasting insulin and leptin levels (p<0.001). Treatment with selected probiotics, butyrate, and propionate caused a significant reduction in blood glucose (p<0.001) and a significant increase in fasting insulin and leptin levels (p<0.001), indicating improved pancreatic function relative to diabetic controls. Diabetic rats displayed severe diabetic dyslipidaemia, with elevated atherogenic lipoproteins and reduced HDL-C (p<0.001). Administration of probiotics, butyrate, and propionate led to a significant reduction in atherogenic lipid levels (p<0.01) and a marked increase in HDL-C compared with diabetic controls. Liver and kidney function markers were significantly elevated in diabetic control rats (p<0.01), whereas these elevations were notably reduced (p<0.01) in all treatment groups. Among these, the combination of butyrate and probiotics exhibited the most pronounced therapeutic benefits (p<0.001 vs. other treatments). Histopathological evaluation revealed severe hepatic and pancreatic abnormalities in diabetic controls, whereas treatment groups exhibited restoration of normal tissue architecture. Notably, butyrate-treated rats showed prominent β-cell hyperplasia and hypertrophy, further supporting enhanced pancreatic regeneration and overall therapeutic efficacy.

Conclusion: This finding suggested that butyrate, in combination with probiotics, has more anti-diabetic effects than individual treatment by increasing the levels of Leptin. These results could potentially lead to the development of novel therapeutic strategies for managing type II diabetes.

References

1. Rajyalakshmi Devi P, Vinyas M, Vinod Kumar N, Srinath M, Mote. Comparative anti-obesity activity of probiotics with short-chain fatty acids (SCFAs) through GLP 1 and PYY activity in high fat diet-induced obesity in rats. TexilaInt J Public Health. 2024;12(3):Art007 https://doi.org/10.21522/TIJPH.2013.12.03.Art007

2. Rajyalakshmi Devi P, Srinath M, Venu T, Nelson VK, Vinyas M. Acute and sub-acute toxicological study of short-chain fatty acids (SCFAs) in rats. Int J Appl Sci Eng [Internet]. 2025;11(4):4424-34. Available from: https://doi.org/10.29294/IJASE.11.4.2025.4424-4434

3.

4. Ezenabor GI, et al. Gut microbiota and metabolic syndrome: relationships and opportunities for new therapeutic strategies. Scientifica. 2024;2024:4222083. https://doi.org/10.1155/2024/4222083

5. Zhou Y, et al. Gut microbiota-derived SCFAs regulate leptinsignaling and improve leptin resistance in obesity and type 2 diabetes models. NutrMetab (Lond). 2023;20:23. https://doi.org/10.1186/s12986-023-00694-2

6. Huang X, et al. Modulating gut microbiota and Leptinsignaling pathways by butyrate improves metabolic parameters in high-fat diet-induced diabetic mice. Front Endocrinol (Lausanne). 2022;13:918456. https://doi.org/10.3389/fendo.2022.918456

7. Zhao L, et al. Butyrate supplementation improves insulin sensitivity and modulates inflammation in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Care. 2022;45(8):1864–72. https://doi.org/10.2337/dc21-1634

8. Bailey CJ. Metformin: historical overview. Diabetologia. 2017;60(9):1566–74. https://doi.org/10.1007/s00125-017-4356-4

9. Cefalu WT, et al. Advances in the science, treatment, and prevention of the disease. Diabetes Care. 2018;41(5):884–93. https://doi.org/10.2337/dci17-0023

10. Den Besten G, et al. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res. 2013;54(9):2325–40. https://doi.org/10.1194/jlr.R039271

11. 10. Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol. 2015;11(10):577–91. https://doi.org/10.1038/nrendo.2015.171

12. Kimura I, et al. The SCFA receptor GPR43 and energy metabolism. Front Endocrinol (Lausanne). 2014;5:85. https://doi.org/10.3389/fendo.2014.00085

13. Heimann E, et al. Butyrate increases leptin production in adipocytes. J NutrBiochem. 2015;26(7):702–8. https://doi.org/10.1016/j.jnutbio.2015.02.009

14. Tolhurst G, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein–coupled receptor FFAR2. Diabetes. 2012;61(2):364–71. https://doi.org/10.2337/db11-0959

15. Gao Z, et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes. 2009;58(7):1509–17. https://doi.org/10.2337/db08-1310

16. Louis P, Flint HJ. Formation of propionate and Butyrate by the human colonic microbiota. Environ Microbiol. 2017;19(1):29–41. https://doi.org/10.1111/1462-2920.13601

17. Hamer HM, et al. Review article: The role of butyrate on colonic function. Aliment PharmacolTher. 2008;27(2):104–19. https://doi.org/10.1111/j.1365-2036.2007.03562.x

18. Slavin J. Dietary fiber and body weight. Nutrition. 2005;21(3):411–8. https://doi.org/10.1016/j.nut.2004.08.017

19. Li J, et al. Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit. Gut. 2018;67(7):1269–79. https://doi.org/10.1136/gutjnl-2017-315789

20. O’Callaghan A, van Sinderen D. Bifidobacteria and their role as members of the human gut microbiota. Front Microbiol. 2016;7:925. https://doi.org/10.3389/fmicb.2016.00925

21. Rivière A, Selak M, Lantin D, Leroy F, De Vuyst L. Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut. Front Microbiol. 2016;7:979. https://doi.org/10.3389/fmicb.2016.00979

22. Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016;165(6):1332–45. https://doi.org/10.1016/j.cell.2016.05.041

23. Wang Y, et al. SCFAs: the link between microbiota and immune response. Inflamm Bowel Dis. 2019;25(6):969–79. https://doi.org/10.1093/ibd/izy342

24. Smith PM, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341(6145):569–73. https://doi.org/10.1126/science.1241165

25. Liu H, et al. Butyrate: a double-edged sword for health? AdvNutr. 2018;9(1):21–9. https://doi.org/10.1093/advances/nmx009

26. Patterson E, et al. Gut microbiota, obesity and diabetes. Postgrad Med J. 2016;92(1087):286–300. https://doi.org/10.1136/postgradmedj-2016-134605

27. Zhang J, et al. Structural modulation of gut microbiota in life-long calorie-restricted mice. Nat Commun. 2013;4:2163. https://doi.org/10.1038/ncomms3163

28. Fava F, et al. The type and quantity of dietary fat and carbohydrate alter faecal microbiome and short-chain fatty acid excretion in a metabolic ward study. Gut. 2013;62(12):1913–21. https://doi.org/10.1136/gutjnl-2012-303953

29. Wu TR, et al. Gut microbiota as diagnostic tools for mirroring disease progression and circulating neutrophil phenotypes in lupus. Sci Rep. 2017;7(1):1–13. https://doi.org/10.1038/s41598-017-09629-5

30. Machate DJ, et al. The gut microbiota as a target for nutritional therapies. Nutrients. 2020;12(5):1127. https://doi.org/10.3390/nu12051127

31. Gerritsen J, et al. Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr. 2011;6(3):209–40. https://doi.org/10.1007/s12263-011-0229-7

32. Panyod S, Wu WK, Ho CT. Dietary therapy and herbal medicine for obesity prevention: potential mechanisms of action. CurrDevNutr. 2020;4(5):nzaa001. https://doi.org/10.1093/cdn/nzaa001

33. Zeng H, et al. Dietary fiber and gut microbiota interactions. Crit Rev Food SciNutr. 2019;59(2):186–96. https://doi.org/10.1080/10408398.2017.1364811

34. Louis P, Flint HJ. Diversity, metabolism, and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS MicrobiolLett. 2009;294(1):1–8. https://doi.org/10.1111/j.1574-6968.2009.01514.x

35. Qin J, et al. A human gut microbial gene catalog established by metagenomic sequencing. Nature. 2010;464(7285):59–65. https://doi.org/10.1038/nature08821

36. Lin HV, et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS One. 2012;7(4):e35240. https://doi.org/10.1371/journal.pone.0035240

37. Haro C, et al. The gut microbial community in metabolic syndrome patients is modified by diet. J NutrBiochem. 2016;27:27–31. https://doi.org/10.1016/j.jnutbio.2015.08.011

38. Schwartz A, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring). 2010;18(1):190–5. https://doi.org/10.1038/oby.2009.167

39. Chambers ES, et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut. 2015;64(11):1744–54. https://doi.org/10.1136/gutjnl-2014-307913

40. De Vadder F, et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell. 2014;156(1–2):84–96. https://doi.org/10.1016/j.cell.2013.12.016

41. Meijer K, et al. Butyrate modulates oxidative stress in adipocytes in a peroxisome proliferator-activated receptor-γ–dependent manner. J Biol Chem. 2010;285(26):21191–9. https://doi.org/10.1074/jbc.M109.088385

42. Wang W, et al. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activating AMP-activated protein kinase in Caco-2 cell monolayers. J NutrBiochem. 2012;23(4):388–96. https://doi.org/10.1016/j.jnutbio.2011.01.007

43. Lu Y, et al. Sodium butyrate exerts anti-inflammatory effects on LPS-stimulated macrophages and dextran sulfate sodium-induced colitis model. J Biomed Biotechnol. 2020;2020:8472639. https://doi.org/10.1155/2020/8472639

44. Canani RB, et al. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol. 2011;17(12):1519–28. https://doi.org/10.3748/wjg.v17.i12.1519

45. Vinolo MA, et al. Regulation of inflammation by short-chain fatty acids. Nutrients. 2011;3(10):858–76. https://doi.org/10.3390/nu3100858

46. Ma X, et al. Sodium butyrate modulates mucosal inflammation and intestinal barrier function in a mouse model of inflammatory bowel disease. Scand J Gastroenterol. 2012;47(5):463–72. https://doi.org/10.3109/00365521.2012.658874

47. Zhang L, et al. Sodium butyrate inhibits inflammation and maintains epithelium barrier function in a TNBS-induced inflammatory bowel disease mice model. IntImmunopharmacol. 2016;36:70–7. https://doi.org/10.1016/j.intimp.2016.04.006

48. Ferreira-Halder CV, Faria AV, Andrade SS. Action and function of Faecalibacteriumprausnitzii in health and disease. Best Pract Res ClinGastroenterol. 2017;31(6):643–8. https://doi.org/10.1016/j.bpg.2017.10.006

49. López-Siles M, et al. Faecalibacteriumprausnitzii: from microbiology to diagnostics and prognostics. ISME J. 2017;11(4):841–52. https://doi.org/10.1038/ismej.2016.176

50. Wang L, et al. Faecalibacteriumprausnitzii produces butyrate to maintain Th17/Treg balance and to ameliorate colorectal colitis by inhibiting histone deacetylase 1. IntImmunopharmacol. 2021;91:107276. https://doi.org/10.1016/j.intimp.2020.107276

51. Martín R, et al. The commensal bacterium Faecalibacteriumprausnitzii is protective in a murine model of colitis. Gut. 2008;57(7):950–7. https://doi.org/10.1136/gut.2007.044834

52. Foditsch C, et al. Oral administration of Faecalibacteriumprausnitzii decreased the severity of symptoms and shortened the duration of diarrhea in a bovine model of enteric disease. BMC Vet Res. 2015;11:67. https://doi.org/10.1186/s12917-015-0383-6

53. Rajilic-Stojanovic M, de Vos WM. The first 1000 cultured species of the human gastrointestinal microbiota. FEMS Microbiol Rev. 2014;38(5):996–1047 https://doi.org/10.1111/1574-6976.12075

54. Scott KP, et al. The influence of diet on the gut microbiota. Pharmacol Res. 2013;69(1):52–60. https://doi.org/10.1016/j.phrs.2012.10.020

55. Holscher HD. Dietary fiber and prebiotics and the gastrointestinal microbiota. Gut Microbes. 2017;8(2):172–84. https://doi.org/10.1080/19490976.2017.1290756